P.D. and M.K. contributed equally to this work.
Coronary Artery Disease
Duration of dual antiplatelet therapy and outcomes after coronary stenting with the genous™ bio-engineered R stent™ in patients from the e-healing registry†
Version of Record online: 8 DEC 2011
Copyright © 2011 Wiley Periodicals, Inc.
Catheterization and Cardiovascular Interventions
Volume 79, Issue 2, pages 243–252, 1 February 2012
How to Cite
Damman, P., Klomp, M., Silber, S., Beijk, M. A., Ribeiro, E. E., Suryapranata, H., Wójcik, J., Sim, K. H., Tijssen, J. G.P., de Winter, R. J. and on behalf of the e-Healing investigators (2012), Duration of dual antiplatelet therapy and outcomes after coronary stenting with the genous™ bio-engineered R stent™ in patients from the e-healing registry. Cathet. Cardiovasc. Intervent., 79: 243–252. doi: 10.1002/ccd.23156
Conflict of Interest: Nothing to report.
- Issue online: 23 JAN 2012
- Version of Record online: 8 DEC 2011
- Accepted manuscript online: 3 MAY 2011 02:17PM EST
- Manuscript Accepted: 19 MAR 2011
- Manuscript Received: 17 MAR 2011
- The e-HEALING Registry and The Academic Medical Center received unrestricted research grant support from OrbusNeich Medical BV, The Netherlands.
- EPC capturing R stent™;
- dual antiplatelet therapy
Objective: We investigated the relation between duration of dual antiplatelet therapy (DAPT) and clinical outcomes up to 12 months after Genous™ endothelial progenitor cell capturing R stent™ placement in patients from the e-HEALING registry. Background: Cessation of (DAPT) has been shown to be associated with the occurrence of stent thrombosis (ST). After Genous placement, 1 month of DAPT is recommended. Methods: Patients were analyzed according to continuation or discontinuation of DAPT at a 30-day and 6-month landmark, excluding patients with events before the landmark. Each landmark was a new baseline, and outcomes were followed up to 12 months after stenting. The main outcome for our current analysis was target vessel failure (TVF), defined as target vessel-related cardiac death or myocardial infarction and target vessel revascularization. Secondary outcomes included ST. (Un)adjusted hazard ratios (HR) for TVF were calculated with Cox regression. Results: No difference was observed in the incidence of TVF [HR: 1.03; 95% confidence intervals (CI): 0.65–1.65, P = 0.89] in patients continuing DAPT (n = 4,249) at 30 days versus patients stopped (n = 309), and HR: 0.82 (95% CI: 0.55–1.23, P = 0.34) in patients continuing DAPT (n = 2,654) at 6 months versus patients stopped [n = 1,408] DAPT). Furthermore, no differences were observed in ST. Even after addition of identified independent predictors for TVF, adjusted TVF hazards were comparable. Conclusions: In a post-hoc analysis of e-HEALING, duration of DAPT was not associated with the occurrence of the outcomes TVF or ST. The Genous stent may be an attractive treatment especially in patients at increased risk for (temporary) cessation of DAPT or bleeding. © 2011 Wiley Periodicals, Inc.